Current status of flavivirus vaccines

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Although there are approximately 68 flaviviruses recognized, vaccines have been developed to control very few human flavivirus diseases. Licensed live attenuated vaccines have been developed for yellow fever (strain 17D) and Japanese encephalitis (strain SA14-14-2) viruses, and inactivated vaccines have been developed for Japanese encephalitis and tick-borne encephalitis viruses. The yellow fever live attenuated 17D vaccine is one of the most efficacious and safe vaccines developed to date and has been used to immunize more than 300 million people. A number of experimental vaccines are being developed, most notably for dengue. Candidate tetravalent live attenuated dengue vaccines are undergoing clinical trials. Other vaccines are being developed using reverse genetics, DNA vaccines, and recombinant immunogens. In addition, the yellow fever 17D vaccine has been used as a backbone to generate chimeric viruses containing the premembrane and envelope protein genes from other flaviviruses. The "Chimerivax" platform has been used to construct chimeric Japanese encephalitis and dengue viruses that are in different phases of development. Similar strategies are being used by other laboratories.

Original languageEnglish (US)
Pages (from-to)262-271
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume951
StatePublished - 2001

Fingerprint

Flavivirus
Attenuated Vaccines
Vaccines
Japanese Encephalitis
Yellow Fever
Viruses
Dengue
Dengue Vaccines
Yellow Fever Vaccine
Tick-Borne Encephalitis Viruses
Japanese Encephalitis Viruses
Reverse Genetics
Inactivated Vaccines
DNA Vaccines
Clinical Trials
Vaccine
Proteins

Keywords

  • DNA vaccines
  • Flavivirus vaccines
  • West Nile virus
  • Yellow fever

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Current status of flavivirus vaccines. / Barrett, Alan.

In: Annals of the New York Academy of Sciences, Vol. 951, 2001, p. 262-271.

Research output: Contribution to journalArticle

@article{e2ec0a2fbdb042f4b9354e4b5c12e669,
title = "Current status of flavivirus vaccines",
abstract = "Although there are approximately 68 flaviviruses recognized, vaccines have been developed to control very few human flavivirus diseases. Licensed live attenuated vaccines have been developed for yellow fever (strain 17D) and Japanese encephalitis (strain SA14-14-2) viruses, and inactivated vaccines have been developed for Japanese encephalitis and tick-borne encephalitis viruses. The yellow fever live attenuated 17D vaccine is one of the most efficacious and safe vaccines developed to date and has been used to immunize more than 300 million people. A number of experimental vaccines are being developed, most notably for dengue. Candidate tetravalent live attenuated dengue vaccines are undergoing clinical trials. Other vaccines are being developed using reverse genetics, DNA vaccines, and recombinant immunogens. In addition, the yellow fever 17D vaccine has been used as a backbone to generate chimeric viruses containing the premembrane and envelope protein genes from other flaviviruses. The {"}Chimerivax{"} platform has been used to construct chimeric Japanese encephalitis and dengue viruses that are in different phases of development. Similar strategies are being used by other laboratories.",
keywords = "DNA vaccines, Flavivirus vaccines, West Nile virus, Yellow fever",
author = "Alan Barrett",
year = "2001",
language = "English (US)",
volume = "951",
pages = "262--271",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Current status of flavivirus vaccines

AU - Barrett, Alan

PY - 2001

Y1 - 2001

N2 - Although there are approximately 68 flaviviruses recognized, vaccines have been developed to control very few human flavivirus diseases. Licensed live attenuated vaccines have been developed for yellow fever (strain 17D) and Japanese encephalitis (strain SA14-14-2) viruses, and inactivated vaccines have been developed for Japanese encephalitis and tick-borne encephalitis viruses. The yellow fever live attenuated 17D vaccine is one of the most efficacious and safe vaccines developed to date and has been used to immunize more than 300 million people. A number of experimental vaccines are being developed, most notably for dengue. Candidate tetravalent live attenuated dengue vaccines are undergoing clinical trials. Other vaccines are being developed using reverse genetics, DNA vaccines, and recombinant immunogens. In addition, the yellow fever 17D vaccine has been used as a backbone to generate chimeric viruses containing the premembrane and envelope protein genes from other flaviviruses. The "Chimerivax" platform has been used to construct chimeric Japanese encephalitis and dengue viruses that are in different phases of development. Similar strategies are being used by other laboratories.

AB - Although there are approximately 68 flaviviruses recognized, vaccines have been developed to control very few human flavivirus diseases. Licensed live attenuated vaccines have been developed for yellow fever (strain 17D) and Japanese encephalitis (strain SA14-14-2) viruses, and inactivated vaccines have been developed for Japanese encephalitis and tick-borne encephalitis viruses. The yellow fever live attenuated 17D vaccine is one of the most efficacious and safe vaccines developed to date and has been used to immunize more than 300 million people. A number of experimental vaccines are being developed, most notably for dengue. Candidate tetravalent live attenuated dengue vaccines are undergoing clinical trials. Other vaccines are being developed using reverse genetics, DNA vaccines, and recombinant immunogens. In addition, the yellow fever 17D vaccine has been used as a backbone to generate chimeric viruses containing the premembrane and envelope protein genes from other flaviviruses. The "Chimerivax" platform has been used to construct chimeric Japanese encephalitis and dengue viruses that are in different phases of development. Similar strategies are being used by other laboratories.

KW - DNA vaccines

KW - Flavivirus vaccines

KW - West Nile virus

KW - Yellow fever

UR - http://www.scopus.com/inward/record.url?scp=0035683635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035683635&partnerID=8YFLogxK

M3 - Article

C2 - 11797783

AN - SCOPUS:0035683635

VL - 951

SP - 262

EP - 271

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -